Company profile
MACROGENICS INC
NASDAQ:MGNXBiotechnology: Pharmaceutical Preparations
Drug pipeline (5)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| MARGENZA | approved | — | 0 | — |
| RETIFANLIMAB | phase3 | — | 28 | active |
| ENOBLITUZUMAB | phase2_3 | — | 5 | completed, terminated, withdrawn |
| OBRINDATAMAB | phase1 | — | 2 | completed, terminated |
| PRV-3279 | phase1 | — | 2 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (39)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05848011 | phase2 | completed | 2023-09-28 | 2026-02-19 | MacroGenics | A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer |
| NCT06730347 | phase2 | recruiting | 2025-05-01 | 2027-07-01 | MacroGenics | A Study of Lorigerlimab in Participants With Advanced Solid Tumors |
| NCT05293496 | phase1 | completed | 2022-04-19 | 2025-06-24 | MacroGenics | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors |
| NCT06242470 | phase1 | recruiting | 2024-03-06 | 2028-05-01 | MacroGenics | A Study of MGC026 in Participants With Advanced Solid Tumors |
| NCT06723236 | phase1 | recruiting | 2025-02-13 | 2026-11-01 | MacroGenics | A Study of MGC028 in Participants With Advanced Solid Tumors |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 761150 | 2020-12-16 | BLA | TERSERA THERAPEUTICS LLC | |||||
Loading… | ||||||||